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The majority of patients at an early stage of gastric carcinoma can
be cured by surgery, but more than one-half of the patients at an
advanced stage of the disease die of carcinoma recurrence, even
when they had undergone curative gastrectomy. Recurrence prob-
ably arises from the growth of occult micrometastasis cells that
have already become established by the time of surgery. It has
been found that identical therapeutic management may lead to
different clinical outcomes, even in patients at the same stage of
the disease. This might be due to the biological characteristics of
the tumour itself or the sensitivity of tumour cells to chemothera-
peutic agents.
Post-operative adjuvant chemotherapy using fluorouracil deriv-
atives (FUs), one of the most widely used chemotherapeutic agents
for the treatment of gastrointestinal tumours, was routinely
performed in advanced gastric carcinoma. However, the efficacy
of this treatment is a subject of debate because the sensitivity of
carcinoma cells to chemotherapeutic agents varies. Thus, identifi-
cation of specific indicators for sensitivity of these carcinoma cells
to anti-cancer drugs would allow a more effective treatment.
It has been reported recently that thymidine phosphorylase (TP)
correlated with unfavourable prognosis of various carcinomas
via neoangiogenesis (Maeda et al, 1996; Takebayashi et al, 1996).
TP was found to be identical to platelet-derived endothelial cell
growth factor (PD-ECGF), which was thought to be an angiogenic
factor (Ishikawa et al, 1989; Moghaddam et al, 1992). More-
over, TP was known to be an enzyme which converted both
1-(tetrahydro-2-furanyl)-5-fluorouracil and 5¢-deoxy-5-fluorouri-
dine (5¢-DFUR) to 5-fluorouracil (5-FU) (Kono et al, 1981, 1983).
Thus, we speculated that the expression of TP might correlate with
the efficacy of chemotherapy using FUs.
In the current study, the expression of TP and the density of
microvessels were examined in advanced gastric carcinoma
patients with serosal invasion, who had undergone curative resec-
tion. Immunohistochemistry investigation was used to evaluate the
correlation between the expression of TP and neoangiogenesis
or the efficacy of chemotherapy using FUs.
MATERIALS AND METHODS
Patients
A total of 126 advanced gastric adenocarcinoma patients with
serosal invasion who had undergone curative gastrectomy at our
institution from January 1976 to December 1995, were used in this
study. The patients’ ages ranged from 24 to 91 years (average
62.2); 70 were male and 56 were female. The clinicopathological
findings were determined according to the rules set forth by the
Japanese Society Committee on Histological Classification of
Gastric Cancer (Japanese Research Society for Gastric Cancer,
1995). Criteria for consideration as curative resection were the
complete removal of a primary gastric tumour, dissection of
regional lymph nodes and no macroscopic tumour being left
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behind. The patients had no metastasis in the liver, peritoneum, or
in distant organs at the time of surgery. No other previous or
concomitant primary cancer was present. Patients had not received
either chemotherapy or radiation therapy before surgery. All had
experienced distal partial gastrectomy, proximal partial gastrec-
tomy, or total gastrectomy with regional lymph node dissection to
group 1 (D1), group 2 (D2), group 3 (D3), or group 4 (D4) by
curative intent. None of the resection margins were positive for
tumours. With regard to adjuvant chemotherapy, tegafur (FT-207,
Taiho Co., Japan) (Palmeri et al, 1990) was used in 51 patients and
uracil-tegafur (UFT, Taiho Co., Japan) (Maehara et al, 1990) in 40
patients; both were administered for 6 months to a year. Of the
patients used in our study, 35 had no chemotherapy with FUs.
These patients received either 600–800 mg FT twice, or 200–
400 mg UFT two or three times daily orally. As a rule, the patients
over 70 years old were not treated with anticancer agents in our
hospital. Thus, the mean age was 57.4 in patients treated with FUs
and 70.9 in patients not treated with FUs; there was a significant
difference (P < 0.0001). However, there was no signficant differ-
ence in other clinicopathological factors (Table 1). Mitomycin C
(MMC) was used in 79 patients as follows: (i) 14 patients –
intraperitoneal administration at a dose of 8–10 mg after surgical
resection; (ii) 58 patients – intravenous administration at a dose of
8–30 mg after surgical resection and/or on the post-operative day;
and (iii) 18 patients – continuous hyperthermic peritoneal perfu-
sion (CHPP) with physiological saline that contained 10 mg ml–1
MMC (Hamazoe et al, 1994). Moreover, cisplatin (CDDP) was
used in 14 patients as follows: (i) six patients – intraperitoneal
administration at a dose of 90–150 mg after surgical resection;
(ii) eight patients – CHPP physiologic saline that contained 125–
150 mg CDDP. Data concerning patients’ outcomes, including
overall survival and either presence or absence of metastases were
available from all patients.
Immunohistochemistry
Thymidine phosphorylase expression
Four-micrometre-thick sections were dewaxed in xylene, dehy-
drated in ethanol and then heated in a microwave oven (700 W) for
10 min to retrieve antigens. Endogenous peroxidase was blocked
by incubation of samples in 3% hydrogen peroxide in methanol.
After being washed with phosphate-buffered saline (PBS), they
were incubated overnight with anti-dThdPase monoclonal anti-
body at a 1:500 dilution. This antibody was obtained from the
Nippon Roche Research Center (Kanagawa, Japan). This antibody
was prepared with an antigen consisting of human dThdPase puri-
fied from human colon cancer xenograft HCT116. The characteri-
zation of this antigen was reported by Nishida et al (1994). Next,
they were incubated with Envision+ reagent (Dako Co. Ltd,
Denmark) for 30 min at room temperature. Envision+ reagent is
peroxidase labelled polymer conjugated to goat anti-mouse
immunoglobulins in Tris–HCl buffer containing carrier protein
and an antimicrobial agent. The reaction products were visualized
with diaminobenzidine as the chromogen and the sections were
counterstained with methyl green. Normal mouse immunoglobulin
G was used instead of the primary antibodies for negative controls.
The degree of monoclonal antibody reactivity with individual
tissue sections was considered positive if unequivocal staining of
cytoplasm or nuclear compartment was seen in more than 5% of
the tumour cells, as previously reported (Takebayashi et al, 1996).
Microvessel detection and counting
A detection procedure for microvessels was performed using
anti-CD34 monoclonal antibody (Nichirei Ltd, Tokyo, Japan).
Envision+ reagent was applied for immunoreaction. A single
microvessel was defined as any brown immunostained endothelial
cell separated from adjacent microvessels, tumour cells, and other
connective tissue elements. The stained sections were screened at
´ 100 magnification (´ 10 objective lens and ´ 10 ocular lens)
under a light microscope (Vanox-S, Olympus, Tokyo, Japan) to
identify the five regions of the section with the highest number of
microvessels. The image was visualized on a computer display
(Macintosh 7500/100, Apple Computer Inc., Cupertino, CA,
USA) through a colour video camera module (XC-003, Sony,
Tokyo, Japan) and colour image freezer (AE-6905C, Atto, Tokyo,
Japan). Microvessels were counted in these areas at ´ 200 magni-
fication (´ 20 objective lens and ´ 10 ocular lens), and the average
numbers of microvessels were recorded. The visualized area on
the display was determined to be 0.075 mm2. Two observers
(ST and HS) did the counting and the mean value was used for
analysis. Large vessels with thick muscular walls were excluded in
the counts. Observation of the lumen was not required for identifi-
cation of a vessel.
Statistical analysis
The association of factors was evaluated by the c2 test. The signifi-
cance of differences among means was determined by Student’s 
t-test or Mann–Whitney U-test. Differences between survival
Table 1 Correlation between the treatment of fluorouracil derivatives and
clinicopathological features
Variables Treatment of fluorouracil derivatives
Treated (n = 91) Untreated (n = 35) P-value
Age (years) 57.4 ± 12.4 70.9 ± 12.5 P < 0.0001
Gender
Male (n = 70) 49 21 NS
Female (n = 56) 42 14
Tumour location
Upper (n = 31) 23 8 NS
Middle (n = 53) 39 14
Lower (n = 42) 29 13
Size (cm) 8.2 ± 3.9 8.2 ± 3.9 NS
Histology
Well differentiated(n = 34) 21 13 NS
Poorly differentiated(n = 92) 70 22
Stage
II (n = 67) 53 14 NS
III (n = 47) 29 18
IV (n = 12) 9 3
Lymphatic involvement
Absent (n = 42) 34 8 NS
Present (n = 84) 57 27
Vascular involvement
Absent (n = 45) 30 15 NS
Present (n = 81) 61 20
Gastric resection
Partial (n = 68) 49 19 NS
Total (n = 58) 42 16
Expression of TP
Positive (n = 71) 51 20 NS
Negative (n = 55) 40 15
NS, not significant.486 H Saito et al
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curves were examined with the generalized Wilcoxon test. The
influence of each variable on survival was assessed by the Cox
proportional hazards model and a step-wise procedure. The
accepted level of significance was P < 0.05. A Macintosh personal
computer system (Stat View software; Abacus Concepts, Inc.,
Berkeley, CA, USA) was used for all statistical analyses.
RESULTS
Normal gastric mucosa was not immunoreactive with anti-
dThdPase monoclonal antibody. TP was distributed in the cyto-
plasm or nuclear compartments of the carcinoma cells and
infiltrating cells (Figure 1). The expression of TP was negative in
72, positive in 54. There was no correlation between the expres-
sion of TP and clinicopathological factors (Table 2). the
microvessel density was 49.0 ± 22.7 in TP-positive tumours and
41.5 ± 15.3 in TP-negative tumours. The expression of TP signifi-
cantly correlated with microvessel density.
The expression of TP significantly correlated with favourable
prognosis in total cases (Figure 2). With regard to the treatment by
FUs, there was no significant difference in prognosis between the
patients treated by FUs and those not treated by FUs in total cases
(data not shown). In patients with TP-positive tumours, however,
the prognosis of patients given FUs was significantly better than
that of those not given FUs (P < 0.05), whereas this difference was
not observed in patients with TP-negative tumours (Figure 3). The
expression of TP significantly correlated with favourable prog-
nosis in patients treated by FUs, and with unfavourable prognosis
in patients not treated by FUs (Figure 4).
Multivariate analysis by Cox proportional hazards model and a
step-wise procedure was performed to determine the significance
of the treatment using FUs based on the status of the expression of
TP. Covariates were: age, gender, tumour size, histology, depth of
invasion, lymph node metastasis, lymphatic vessel invasion, blood
vessel invasion, lymph node dissection, treatment by FUs, treat-
ment by MMC, treatment by CDDP and treatment by CHPP.
Treatment by FUs and lymph node metastasis were independent
prognostic factors in the patients with TP-positive tumours using
Cox proportional hazards model. Depth of invasion and lymphatic
vessel invasion were independent prognostic factors in patients
with TP-negative tumours (Table 3). Moreover, multivariate
analyses were performed based on the treatment by FUs. The
expression of TP and lymph node metastasis were independent
prognostic factors in the patients given FUs, and only lymph node
metastasis was an independent prognostic factor in the patients not
given FUs (Table 4).
DISCUSSION
Solid tumours require neovascularization for growth and metas-
tasis (Folkman, 1990). It is also thought that the degree of tumour
Table 2 Correlation between the expression of TP and clinicopathological
features
Variables Expression of TP
Positive (n = 54) Negative (n = 72) P-value
Age (years) 60.7 ± 14.3 61.5 ± 13.6 NS
Gender
Male (n = 70) 34 36 NS
Female (n = 56) 20 36
Tumour location
Upper (n = 31) 13 18 NS
Middle (n = 53) 24 29
Lower (n = 42) 17 25
Size (cm) 8.1 ± 3.5 8.3 ± 4.2 NS
Histology
Well differentiated (n = 34) 15 19 NS
Poorly differentiated (n = 92) 39 53
Lymph node metastasis
Absent (n = 70) 32 38 NS
Present (n = 56) 22 34
Lymphatic involvement
Absent (n = 42) 16 26 NS
Present (n = 84) 38 46
Vascular involvement
Absent (n = 45) 18 27 NS
Present (n = 81) 36 45
Gastric resection
Partial (n = 68) 29 39 NS
Total (n = 58) 25 33
Lymph node dissection
D1 and D2 (n = 57) 20 37 NS
D3 and D4 (n = 69) 34 35
Treatment of fluorouracil derivatives
Treated (n = 91) 40 51 NS
Untreated (n = 35) 14 21
NS, not significant
A
B
Figure 1 Typical results of immunohistochemistry. (A) TP immunoreactivity
was mainly identified in the cytoplasm or nuclear compartments of the
carcinoma cells and infiltrating cells (magnification ´ 500)
(B) Immunostaining for anti-CD34 antibody (magnification ´ 500)Thymidine phosphorylase in gastric cancer 487
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angiogenesis is related to clinical outcome; angiogenetic proper-
ties are believed to correlate with tumour aggressiveness (Bosari et
al, 1992; Weidner et al, 1992; Gasparini et al, 1994; Maeda et al,
1995). Many investigators have demonstrated that tumour cell
secretion and activation of various endothelial growth factors,
termed angiogenic factors, play crucial roles in the formation of
the neovascularization (Kono et al, 1981; Zagzag et al, 1990; Toi
et al, 1994). In the current study, we determined the correlation
between the expression of TP and the microvessel density in
advanced gastric carcinoma. The microvessel density in the
TP-positive tumour was significantly higher than that in TP-
negative tumour. This result is consistent with a previous report
(Maeda et al, 1996).
The prognosis of patients with TP-positive tumours, however,
was significantly better than that of patients with TP-negative
tumours. Because high microvessel density correlates with poor
prognosis in gastric carcinoma (Maeda et al, 1995), as mentioned
above, the present findings appear to be rather paradoxical. In fact,
Maeda et al reported that the expression of TP correlated with
unfavourable prognosis in patients with gastric carcinoma,
including the early stage of the disease (Maeda et al, 1996). Thus,
we determined the correlation between the expression of TP and
post-operative adjuvant chemotherapy using FUs, which were the
most widely used chemotherapeutic agents for the treatment of
gastric carcinoma in Japan. Both tegafur and uracil-tegafur are
5-FU prodrugs which can be given orally. Recently, it was reported
that the expression of TP correlated with the efficacy of 5¢-DFUR
which was one of the 5-FU prodrugs because TP converted
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Figure 2 The correlation between prognosis and the expression of
thymidine phosphorylase. The prognosis of the patients with the expression
of thymidine phosphorylase is better than that of those without the
expression of thymidine phosphorylase (P < 0.05)
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Figure 3 (A) The correlation between the treatment of fluorouracil
derivatives and prognosis in patients with the expression of TP. The prognosis
of patients treated with fluorouracil derivatives was significantly better than
that of the patients untreated with fluorouracil derivatives (P<0.001). (B) The
correlation between the treatment of fluorouracil derivatives and prognosis in
patients without the expression of TP. There was no correlation between the
treatment of fluorouracil derivatives and prognosis
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Figure 4 (A) The correlation between the expression of TP and prognosis
in patients treated with fluorouracil derivatives. The prognosis of the patients
with the expression of thymidine phosphorylase was better than that of the
patients without the expression of thymidine phosphorylase (P < 0.001).
(B) The correlation between the expression of TP and prognosis in patients
untreated with fluorouracil derivatives. The prognosis of the patients with the
expression of thymidine phosphorylase was worse than that of the patients
without the expression of thymidine phosphorylase (P < 0.05)488 H Saito et al
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5¢-DFUR to 5-FU (Haraguchi et al, 1993; Ishikawa et al, 1998). TP
is also one of the enzymes that converted tegafur and uracil-
tegafur to 5-FU (Kono et al, 1981, 1983). These findings imply
that the expression of TP might correlate with the efficacy of
chemotherapy using tegafur and uracil-tegafur.
There was no significant difference in prognosis between the
patients treated by FUs and those not treated by FUs in total cases.
In patients with TP-positive tumours, however, the prognosis of
patients treated by FUs was significantly better than that of those
not treated by FUs. Moreover, treatment by FUs and lymph node
metastasis were independent prognostic factors in the patients with
TP-positive tumours using Cox proportional hazards model. In
addition, the expression of TP and lymph node metastasis were
independent prognostic factors in the patients given FUs, although
only lymph node metastasis was an independent prognostic factor
in the patients not given FUs. These results indicated that the
expression of TP in tumour cells might closely correlate with the
efficacy of chemotherapy using FUs. The prognosis of the patients
with TP-positive tumours was worse than that of those with TP-
negative tumours who were not treated by FUs. Since a larger
number of patients were treated by FUs, our results might be
different from the results of previous studies. On the other hand,
with regard to the efficacy of other adjuvant chemotherapy except
FT and UFT (CDDP, MMC and CHPP), the prognosis of patients
given MMC was significantly better than that of patients not given
MMC (data not shown). However, there were no significant differ-
ences in prognosis in the treatment by CDDP and CHPP.
Multivariate analysis indicated that these treatments were not inde-
pendent prognostic factors in both status of the expression of TP.
Chemotherapy is not generally believed to be very effective for
the eradication of massive tumours. However, it can be used to
advantage against micrometastases invading the lymph node
and/or lymph vessels and disseminated in the abdominal cavity
after curative resection (Griswold et al, 1975; Schabel et al, 1976;
Schabel et al, 1977). Patients included in the current study had
undergone curative gastrectomy. Thus, the correlation between the
expression of TP and the efficacy of chemotherapy using FUs
might be clear. The efficacy of chemotherapy is presumably
dependent on the sensitivity of the tumour cells, which in turn is
determined partially by the growth rate. Kubota et al (1995)
reported that the overall survival rate of the chemo-sensitive group
was significantly better than that of the chemo-resistant group
according to the blind study in which their chemo-sensitivity was
evaluated by histoculture drug response assay (HDRA). If patients
with tumours sensitive to FUs can be identified before the initia-
tion of therapy, FU-based treatment could be selected for this
group. Such selection ability would spare patients unlikely to
respond to the toxicity of anticancer agents and would allow faster
progress in new drug development. It has been reported that the
expression of thymidine synthetase (TS) correlated with sensi-
tivity to FUs (Lenz et al, 1995; Leichman et al, 1997). The
determination of the expression of TP might also be useful for the
purpose of treatment selection. The background of patients treated
by FUs, however, was different from that of patients not treated by
FUs in this retrospective study. Thus, it is necessary for our
findings to be confirmed in randomized controlled studies.
In conclusion, we indicated the close relationship between the
expression of TP and microvessel density or the efficacy of
chemotherapy using FUs. Determination of the intra-tumoural
expression of TP may enable clinicians to decide rationally
whether FUs are appropriate first line chemotherapy on a patient-
by-patient basis.
Table 3 Association of various factors with overall survival determined by the Cox proportional hazards model and a
stepwise procedure in each status of PyNPase expression
PyNPase-negative PyNPase-positive
Prognostic factors P Hazard ratio P Hazard ratio
Depth of invasion (t3 or t4)a 0.0021 7.086 – –
Lymph node metastasis (n0-n3)b – – 0.0006 2.020
Lymphatic vessel invasion (ly0-1y1)c 0.0093 1.374 – –
Treatment of 5-FU (treated or untreated) – – 0.0251 2.993
at3, penetrating the serosa; t4, invading adjacent organs. bn0, no regional lymph node metastasis; n1, n2 and n3,
metastasis in groups 1, 2 and 3 lymph nodes respectively. cLymphatic invasion: 1y0-1y3, grade of lymphatic vessel
invasion.
Table 4 Association of various factors with overall survival determined by the Cox proportional hazards model and a stepwise
procedure in both patients given FUs and those not given FUs
Treatment of fluorouracil derivatives
Treated Untreated
Prognostic factors P Hazard ratio P Hazard ratio
Lymph node metastasis (n0-n3)a 0.0019 1.615 0.0076 1.761
Expression of TP (positive or negative) 0.0009 0.284 – –
an0, no regional lymph node metastasis; n1, n2 and n3, metastasis in groups 1, 2 and 3 lymph nodes respectively.Thymidine phosphorylase in gastric cancer 489
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